FUNI (Hypha Labs) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hypha Labs Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FUNI vs ISPC, BIAF, IVRO: Short Interest Comparison

For the Diagnostics & Research subindustry, Hypha Labs's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hypha Labs Short Interest vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hypha Labs's Short Interest distribution charts can be found below:

* The bar in red indicates where Hypha Labs's Short Interest falls into.


Hypha Labs Business Description

Address 5940 S. Rainbow Boulevard, Las Vegas, NV, USA, 89118
Hypha Labs Inc engaged in the research, development, and commercialization of the Hypha Micropearl accelerator, an in-home, web-based, computer-controlled bioreactor designed to accelerate the production of nutritionally beneficial mushrooms for human consumption. The Company's easy-to-use device, together with replaceable cartridges ordered through its exclusive app, safely and effectively produced enriched mycelium of functional mushrooms, or Micropearls, in eight days. These Micropearls contained active mushroom ingredients in a concentrated, easy-to-handle, tasteless, and odorless form that could be incorporated into various foods and beverages without altering flavor.